Therapeutics News and Research

RSS

Nanomaterials database restructured to improve functionality, add scientific credibility

Nanomaterials are the heart of the smaller, better electronics developed during the last decade, as well as new materials, medical diagnostics and therapeutics, energy storage, and clean water. However, exposure to nanomaterials may have unintended consequences for human health and the environment.

29 Oct 2013

Pulmatrix reports positive results from initial PUR0200 Phase IB clinical study in COPD

Pulmatrix today announced the successful completion and positive results of the first part of a two-part Phase IB clinical study in chronic obstructive pulmonary disease (COPD) patients with their lead clinical candidate PUR0200.

29 Oct 2013

NHMRC awards over $6M for Griffith University research projects

Griffith University research projects have been awarded just over $6m in research funding by the prestigious National Health and Medical Research Council.

28 Oct 2013

State highlights: 'Habilitation' an essential benefit, but what is it?; Va. gov. candidates differ on mental health system; Calif. pays $2.7M for late hearings

A selection of health policy stories from Virginia, California, Colorado, Missouri, Pennsylvania, Kansas and Texas.

25 Oct 2013

Study finds persistent deficiency in new therapeutics for neglected diseases

In a study published today in the open-access journal The Lancet Global Health, the Drugs for Neglected Diseases initiative and other researchers report a persistent deficiency in truly new therapeutics for neglected diseases, despite nominal progress and an acceleration in research and development efforts. This continued 'fatal imbalance' in medical R&D points to the urgent need to develop and deliver groundbreaking new treatments for the world's poorest and most neglected patients.

25 Oct 2013

Study: Investigational drug shows promise against pancreatic cancer

An investigational drug that disrupts tumor blood vessels shows promise against a rare type of pancreatic cancer, scientists at Albert Einstein College of Medicine of Yeshiva University have found. Their results were presented October 20 during a poster session at an international cancer conference.

25 Oct 2013

Hands-free ultrasound device with clot-busting drug safe for ischemic stroke patients

A study led by researchers at The University of Texas Health Science Center at Houston (UTHealth) showed that a hands-free ultrasound device combined with a clot-busting drug was safe for ischemic stroke patients.

25 Oct 2013

Common food additive can block new strain of avian influenza virus

A common food additive can block a deadly new strain of avian influenza virus from infecting healthy cells, report researchers at the University of Illinois at Chicago College of Medicine in the online journal, PLOS ONE.

24 Oct 2013

Diffregen awarded SBIR Phase 1 grant to advance Angiocidin towards human clinical trials

Diffregen LLC, a Temple University startup company, has been awarded a small business innovation research Phase 1 grant by the National Cancer Institute to advance Angiocidin, a university-created therapeutic to treat acute myeloid leukemia, to the doorstep of human clinical trials.

24 Oct 2013

UHN, Boehringer Ingelheim partner to improve care, education and support for hepatitis C patients

In a move to address a significant unmet need in hepatitis C in Canada, the University Health Network, together with Boehringer Ingelheim (Canada) Ltd., announced today a multi-year partnership that aims to improve care, education and support for patients with hepatitis C. The program, known as Link-C, aims to improve access to hepatitis C care and treatment in remote areas of Ontario and other parts of Canada.

23 Oct 2013

Promising technique for treating eye disease proves effective in preclinical studies

A promising technique for treating human eye disease has proven effective in preclinical studies and may lead to new treatments to prevent blindness, according to experiments conducted at The Scripps Research Institute in La Jolla, California.

23 Oct 2013

Functional biomarker could help guide treatment of patients with BRAF-mutant melanomas

A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

23 Oct 2013

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

23 Oct 2013

New MDx prototype platform can detect BRAF V600 mutations in 90 minutes

A new diagnostic platform to detect BRAF mutations in melanoma and other cancer types is faster and more accurate compared with the standard method currently used in clinics, and this could help accelerate diagnosis and treatment, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

23 Oct 2013

GenSpera presents final data from G-202 Phase I clinical trial at EORTC-NCI-AACR Symposium

GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA.

23 Oct 2013

Angiochem presents results of Phase 2 study with ANG1005 in breast cancer patients with brain metastases

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), announced that the complete analysis results of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in breast cancer patients with brain metastasis were presented today at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference.

23 Oct 2013

Pfizer to continue development of Remoxy Extended-Release Capsules CII

Pfizer Inc. announced today that, having achieved technical milestones related to manufacturing, it will continue the development program for Remoxy (oxycodone) Extended-Release Capsules CII.

22 Oct 2013

Buck Institute finds link between ApoE4 and anti-aging protein targeted by resveratrol in red wine

he major genetic risk factor for Alzheimer's disease (AD), present in about two-thirds of people who develop the disease, is ApoE4, the cholesterol-carrying protein that about a quarter of us are born with. But one of the unsolved mysteries of AD is how ApoE4 causes the risk for the incurable, neurodegenerative disease.

22 Oct 2013

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

22 Oct 2013

Pancreatic cancer patients may benefit from antibody-drug conjugates

Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

22 Oct 2013

Therapeutics News and Research

Nanomaterials database restructured to improve functionality, add scientific credibility

Pulmatrix reports positive results from initial PUR0200 Phase IB clinical study in COPD

NHMRC awards over $6M for Griffith University research projects

State highlights: 'Habilitation' an essential benefit, but what is it?; Va. gov. candidates differ on mental health system; Calif. pays $2.7M for late hearings

Study finds persistent deficiency in new therapeutics for neglected diseases

Study: Investigational drug shows promise against pancreatic cancer

Hands-free ultrasound device with clot-busting drug safe for ischemic stroke patients

Common food additive can block new strain of avian influenza virus

Diffregen awarded SBIR Phase 1 grant to advance Angiocidin towards human clinical trials

UHN, Boehringer Ingelheim partner to improve care, education and support for hepatitis C patients

Promising technique for treating eye disease proves effective in preclinical studies

Functional biomarker could help guide treatment of patients with BRAF-mutant melanomas

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

New MDx prototype platform can detect BRAF V600 mutations in 90 minutes

GenSpera presents final data from G-202 Phase I clinical trial at EORTC-NCI-AACR Symposium

Angiochem presents results of Phase 2 study with ANG1005 in breast cancer patients with brain metastases

Pfizer to continue development of Remoxy Extended-Release Capsules CII

Buck Institute finds link between ApoE4 and anti-aging protein targeted by resveratrol in red wine

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Pancreatic cancer patients may benefit from antibody-drug conjugates

Understanding the DNA Damage Response in Innate Immunity eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News